



June 25, 2024

JCR Pharmaceuticals Co., Ltd.

Translation

## JCR Pharmaceuticals Regains Full Commercialization Rights to JR-141

June 25, 2024 -- [JCR Pharmaceuticals Co., Ltd.](#) (TSE 4552: Chairman and President Shin Ashida, “JCR”) announced it has regained full commercialization rights to JR-141 (INN: pabinafusp alfa) following a mutual agreement with Takeda Pharmaceutical Company Limited (“Takeda”) to terminate their collaboration on JR-141, following Takeda’s strategic assessment of the alliance. All licenses and commercialization rights will revert to JCR. This change does not impact the ongoing STARLIGHT Study (NCT04573023) as JCR has led the clinical development of JR-141 from the start and will continue to conduct the global Phase 3 clinical trials of JR-141 in the United States, Latin America, and Europe, as originally planned.

“We are deeply grateful to Takeda for the partnership over the last 3 years and for their commitment to collaborating with us,” said Shin Ashida, Chairman and President of JCR, “With global commercialization rights reverted to JCR, our commitment to accelerating the global clinical trials of JR-141 remains unwavering. JR-141 has been approved in Japan and marketed since May 2021 as IZCARGO® IV infusion 10mg. After 3 years on the market in Japan, the number of patients being treated with this product is steadily increasing. Based on the success of JR-141 in Japan, we look forward to bringing this innovative medicine to patients and their families beyond Japan as soon as possible.”

The impact of this announcement on JCR's consolidated financial results for this fiscal year (ending March 2025) is expected to be minor.

### About JR-141

JR-141, a treatment for Hunter syndrome (Mucopolysaccharidosis type II or MPS II), is designed to deliver therapeutic enzymes to the central nervous system (CNS) using JCR's proprietary blood-brain barrier (BBB) technology, J-Brain Cargo®. This innovative approach allows JR-141 to address both somatic and neuronopathic manifestations of the disease. JR-141 is the world's first biopharmaceutical product that can penetrate the BBB and has been approved in Japan and marketed since May 2021 as IZCARGO® IV infusion 10mg.

### About the J-Brain Cargo® Platform Technology

J-Brain Cargo® is a proprietary BBB-penetrating technology to bring biotherapeutics into the CNS. In addition to JR-141, JCR is leveraging the J-Brain Cargo® platform to advance other enzyme replacement therapies for lysosomal storage disorders and to pioneer new treatments for neurodegenerative conditions (including Alzheimer's), neuroinflammation, epilepsy, and neuro-oncology.

**About JCR Pharmaceuticals Co., Ltd.**

JCR Pharmaceuticals Co., Ltd. (TSE 4552) is a global specialty pharmaceuticals company that is redefining expectations and expanding possibilities for people with rare and genetic diseases worldwide. We continue to build upon our 49-year legacy in Japan while expanding our global footprint into the US, Europe, and Latin America. We improve patients' lives by applying our scientific expertise and unique technologies to research, develop, and deliver next-generation therapies. Our approved products in Japan include therapies for the treatment of growth disorder, MPS II (Hunter syndrome), Fabry disease, acute graft-versus host disease, and renal anemia. Our investigational products in development worldwide are aimed at treating rare diseases including MPS I (Hurler, Hurler-Scheie and Scheie syndrome), MPS II, MPS IIIA and B (Sanfilippo syndrome type A and B), and more. JCR strives to expand the possibilities for patients while accelerating medical advancement at a global level. Our core values – reliability, confidence, and persistence – benefit all our stakeholders, including employees, partners, and patients. For more information, please visit <https://www.jcrpharm.co.jp/en/site/en/>.

Contact:

Investors &amp; Media:

JCR Pharmaceuticals Co., Ltd.

Corporate Communications

[ir-info@jp.jcrpharm.com](mailto:ir-info@jp.jcrpharm.com)

###